Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A group of monoclonal antibodies against gastric cancer, pooled in equal proportions, was used to investigate their corresponding antigens (MG-Ags) in serum and body fluid of patients with gastrointestinal cancer and benign diseases using microsphere-ELISA method. The mean serum level (plus 3 standard deviations) in 59 normal subjects was arbitrarily set as the positive threshold value. The positive rate was found to be 68.8% (135/196) in sera of patients with gastric cancer, 70% (14/20) in colonic cancer, 72.2% (24/33) in rectal cancer, 43.8% (7/16) in esophageal cancer, 45.5% (5/11) in cholecystic cancer and 34.9% (15/43) in lung cancer, which, however, was not found in primary liver cancer, pancreatic cancer and ovarian cancer. In 214 patients with benign diseases, a false positive rate was 7.48%. In gastric juice and ascitic fluid of patients with gastric cancer, the positive rates were found to be 61.7% (27/44) and 83.3% (20/24) respectively. These antigens were also determined repeatedly in sera of patients with gastric cancer who had undergone gastrectomy. It was found that the level of MG-Ags in sera began to decrease at 8-10 days after operation. These results suggest that the determination of MG-Ags is useful in the diagnosis of gastrointestinal cancer and evaluation of the treatments.
 ...
PMID:Diagnostic significance of gastric cancer associated antigens (MG-AGS) in serum, ascitic fluid and gastric juice. 206 47

Dose intensity in cancer chemotherapy proposed by Green (1980) and Hryniuk (1984) is a concept of expressing treatments in terms of how much drug is given per unit time (mg/m2/week). It is expected that the dose intensity may clear dose-response relationships which are sometimes obscure in cancer chemotherapy because dose reduction or treatment delay caused by adverse effects. Good correlations between dose intensity and prognosis of cancer patients are observed in breast, lung, ovarian cancer and malignant lymphoma. But only few trials using dose intensity concepts have been performed in chemotherapy for gastric cancer. A randomized controlled trial targeted for dose intensity itself will be necessary to confirm the usefulness of dose intensity concepts.
 ...
PMID:[Dose intensity in cancer chemotherapy in gastric cancer]. 212 Nov

A histochemical localization of TAG72, obtained through a reaction to MoAb CC49 and B72.3 in gastric cancer tissues, demonstrated a negative reaction in normal epithelium and a positive reaction in the cellular membranes of patients with enteric metaplasia and/or a well-differentiated adenocarcinoma, as well as a positive reaction in the cytoplasm in the majority of patients with a gastric adenocarcinoma. A CA72-4 (TAG72) serum assay was conducted on those with a gastric cancer and/or another malignant disease and then compared with other tumor markers. The overall positive rate of CA72-4 in patients with a malignant disease was 33.1% (59/178 cases). A significant elevation was found in cases of a colonic, gastric, and ovarian cancer, 55.0%, 53.3%, 54.5%, respectively.
 ...
PMID:[Histological localization of TAG72 in gastric cancers and a clinico-pathological study of the CA72-4 serum values]. 216 68

From nude mouse tumors, in which malignantly transformed Bloom's syndrome (BS) B-lymphoblastoid cell lines were successfully transplanted into s.c. tissues, we have detected strong expression of malignant lymphoma (ML)-associated antigen on the cell surface, by using diluted sera of ML patients and indirect immunofluorescence. Even though carcinogen-treated BS B-lymphoblastoid cell lines expressed various types of cancer antigens (ML, ovarian cancer, stomach cancer, lung cancer, liver cancer, etc.) on the cell membrane as a mixed population (Y. Shiraishi and H. Soma, Proc. Natl. Acad. Sci. USA, 85:8211-8215, 1988), the finding that BS malignant cells originating from nude mouse tumors expressed specific ML-associated antigen seemed significant for ML diagnosis. BS nude mouse tumors were successively transplantable from nude mice to nude mice (100%). Histopathological studies using an electron microscope demonstrated that most tumor cells in s.c. tissues of nude mice were lymphoid malignant cells. Gel electrophoresis and Western blotting analyses demonstrated that the antigen which characterized ML was a single band (Mr 97,000) and did not cross-react with the sera of other cancer patients or with normal sera. Chromosome analysis showed that the cell clones with ML-associated antigen had marker chromosomes involving t(6;?)(p25;?),t(9;?)(q34;?), del(10)(p13),t(12;14)(q24;q11). The expression of ML-associated antigen was also discussed in relation to the marker chromosomes.
 ...
PMID:Malignant lymphoma antigen expressed in nude mouse tumor cells derived from carcinogen-transformed Bloom's syndrome B-lymphoblastoid cell lines. 218 81

Cancer incidence in migrants to New South Wales (NSW) from individual countries within the British Isles has been compared with that in the Australian-born population using data from the NSW Central Cancer Registry for the period 1972-84. Indirectly age-standardised incidence ratios (SIR) showed that, for cancer at all sites combined, Scottish migrants had a significantly higher, and English migrants a lower, incidence than the native-born Australians. Melanoma of skin was less common in migrants from all four countries while lung cancer was more common. In all except the Irish migrants, stomach cancer was more frequent than in the Australian-born. Raised SIRs for bladder cancer were found in men from all the countries and for breast cancer in all except the Irish women but only in the English migrants were these ratios significant. English migrants differed from those from Wales, Scotland and Ireland in that, compared with the Australian-born, they had significantly lower SIRs for cancer of the colon (both sexes), head and neck, larynx and prostate (men), gallbladder and kidney (women), and a higher SIR for ovarian cancer. Bone cancer was relatively more common in men born in Wales. 'Other genital' cancers (penis and scrotum; vulva and vagina) tended to be more frequent in migrants from each country than in the Australian-born.
 ...
PMID:Cancer incidence in migrants to New South Wales from England, Wales, Scotland and Ireland. 225 32

The incidence of cancer in migrants to New South Wales (NSW) from Italy, Greece, Yugoslavia, Germany, the Netherlands, Poland and USSR has been compared with that in the Australian-born population using data from the NSW Central Cancer Registry for 1972-84. The indirectly age-standardized incidence ratios (SIR) in all seven countries were low for melanoma of skin and high for gastric cancer. Cancers of the colon, oesophagus and lip also tended to have low SIRs. Migrants from Italy, Greece and Yugoslavia had significantly less cancer at all sites than the native-born Australians mainly due to low SIRs for cancers of colon, lung (except Yugoslavian-born men), prostate and, in men, 'head and neck' (excluding nasopharynx). Cancers of breast and testis were relatively less common in migrants from Italy and Yugoslavia. SIRs were high for cancers of bladder (in Italian-born men), liver (in Greek- and Yugoslavian-born men) and nasopharynx (in Greek-born men and Italian-born men and women). Amongst migrants from the four more northerly European countries, ovarian cancer was relatively more common in women from Germany and Poland as was bladder cancer in men, but not women, from Germany and the Netherlands. Cancers which had significantly increased SIRs in one migrant group only were lung (Dutch-born men), cervix uteri and body of uterus (German-born women), gallbladder and bile ducts (Polish-born women), thyroid (Italian-born women), connective and other soft tissue (Russian-born men) and brain (Greek-born men and women computed together). Lymphomas were relatively less common in men born in Yugoslavia.
 ...
PMID:Cancer incidence in European migrants to New South Wales. 226 68

In attempts to increase the specificity of the CA 12-5 test the ratio of CA 12-5 and CEA concentrations has been determined in 155 cancer patients, all of whom had an increased serum CA 12-5. The patients included 47 with epithelial ovarian cancer, 38 with colorectal cancer, 24 with cervical cancer, 20 with lung cancer, 17 with gastric cancer, and 9 with pancreatic cancer. The CA 12-5/CEA ratio in serum of patients with ovarian cancer ranged from 30 to 920 (mean 251), whereas in other types of cancer the highest ratio was 240 and the mean was 13. All 47 patients with ovarian cancer, but only 7 of the 108 patients with other types of cancer, showed a CA 12-5/CEA ratio greater than 25. About 10% of the patients with gastric or colorectal cancer but none of those with other types of cancer showed an increased ratio. As the predictive value of a CA 12-5/CEA ratio of less than 25 excluding ovarian cancer is 100%, we recommend measuring the CEA concentration in all those with increased CA 12-5 and calculation of the CA 12-5/CEA ratio.
 ...
PMID:Serum CA 12-5 concentrations and CA 12-5/CEA ratios in patients with epithelial ovarian cancer. 235 47

Epirubicin (trade name: Falmorubicin) is a stereoisomer, in which the hydroxyl group of doxorubicin is inverted at position 4', and has the similar mechanism of action as that of doxorubicin; namely, this new anthracycline anticancer agent for injection shows a wide antitumor spectrum and strong antitumor activity via the inhibition of DNA and RNA synthesis. In non-clinical experiments, the effect of epirubicin on transplantable murine tumors was similar or superior to that of doxorubicin in rats and mice. As for pharmacodynamics, this drug was found to rapidly penetrate into the tissue from the blood, and to remain there for a long period of time. This drug has been widely used abroad for the treatment of various solid cancers, such as breast cancer, and tumors of hematopoietic organs, such as malignant lymphoma. In Japan, it was proved clinically that the drug was effective on a wide range of tumors, including acute leukemia, malignant lymphoma, breast cancer, ovarian cancer, gastric cancer, hepatic cancer and ureteral epithelioma(bladder cancer, renal cancer and ureteral cancer). In a comparative study of chronic cardiotoxicity, it was noted that epirubicin produced less damage to the myocardium than doxorubicin when every morphological change was examined as an indicator. Electrocardiographic and histopathological findings also disclosed that epirubicin exhibited a smaller effect on the myocardium than that of doxorubicin. In conclusion, epirubicin is a new antitumor agent having an antitumor effect similar or superior to that of doxorubicin with the various toxicities, including cardiotoxicity, which are reduced in this drug in comparison to those of doxorubicin.
 ...
PMID:[Epirubicin (4'-epi-adriamycin]. 240 56

CA 72 is a monoclonal antibody (MAb) -defined antigenic determinant expressed on a pancarcinoma antigen (TAG-72) found in more than 85% of human colorectal carcinomas. An immunoradiometric assay has been developed using the murine MAb B72.3 to quantitate CA 72 in human serum. In a simultaneous immunoradiometric assay, the mean CA 72 concentration in 1,099 serum samples from healthy blood donors was 1.83 +/- 2.03 (SD) units/ml. If the upper limit of normal was set at 10 mu/mol of serum, a value including 99% of healthy blood donors, only 4 of 101 serum samples (4%) from patients with benign disease were elevated, whereas 15 of 26 (58%) and 14 of 25 (56%) of rectal and colon carcinoma patient sera, respectively, were positive. Serum samples from 84 benign colorectal disease cases were examined; of these, 0 of 28 (0%) colorectal adenoma, 1 of 39 (3%) ulcerative proctocolitis, 0 of 15 (0%) diverticulosis, and 0 of 2 (0%) irritable bowel disease sera contained more than 10 mu/ml CA 72. At a reference value of 20 mu/ml, 0 of 101 (0%) benign disease and 2 of 1,060 (0.2%) blood donor sera had elevated values, whereas 10 of 26 (38%) and 9 of 25 (36%) rectal and colon patient sera, respectively, remained positive. The majority of patients with pancreatic and ovarian cancer, and a significant fraction of stomach cancer patient sera, also contained elevated levels of CA 72. The ability of this assay to discriminate between malignant and benign diseases suggests its further evaluation for monitoring and diagnosis in groups at risk for development of cancer.
 ...
PMID:Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). 242 34

Drug resistant phenomenon to antitumor agents remains a major problem in cancer chemotherapy. In this study, we attempted to overcome drug resistance using high-dose chemotherapy with autologous bone marrow transplantation (ABMT). The main regimen consisted of Cyclophosphamide 60 mg/kg/day and thio-TEPA 6 mg/kg/day which were infused for 3 consecutive days. Three patients with malignant lymphoma, four with breast cancer, two with gastric cancer and one with ovarian cancer. All of whom were refractory to conventional chemotherapies were treated. The overall response rate was 70%. Severe bone marrow suppression, mucositis and diarrhea were observed in all patients, but these were not life-threatening and clinically manageable. Furthermore, the administration of granulocyte colony stimulating factor (G-CSF) has significantly (p less than 0.05) shortened the duration of leukopenia, and has been judged to be useful for reducing severe infections and for shortening the period stayed in clean room. Our results indicates that high-dose chemotherapy with ABMT is an effective method for overcoming drug resistance.
 ...
PMID:[A study to overcome drug resistance using high-dose chemotherapy with autologous bone marrow transplantation]. 247 62


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>